After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...

Cellares will adapt and automate the SBT-77-7101 manufacturing process from Sonoma for use with Cell Shuttle.

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...

The MarketWatch News Department was not involved in the creation of this content. -- New investors include T. Rowe Price Investment Management, Inc., Baillie Gifford, Duquesne Family Office, Intuitive ...

Automated cell manufacturing company Mytos has signed an agreement with Aspen Neuroscience, a clinical-stage private company focused on autologous regenerative medicine, to automate the manufacture of ...

Cellular Origins, Resolution Therapeutics, and Cell and Gene Therapy Catapult (CGT Catapult) say they set up a project aimed at using novel technologies to deliver a hyper-efficient, fully automated, ...

Ori Biotech has lassoed a significant milestone for its space- and cost-efficient cell and gene therapy manufacturing platform. The FDA has granted the company’s IRO platform an Advanced Manufacturing ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford ...